BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — China Net Product Revenue by Quarter
BRUKINSA — China Net Product Revenue ($M) ($M)
BeOne Medicines BRUKINSA — China Net Product Revenue: $97.2M in Q2 2026, up 16.8% from a year earlier. That is the highest of the 19 quarters on record here.
Where the Q2 2026 figure comes from
“BRUKINSA sales in China totaled $97.2 million, representing growth of 16.7%”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — China Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 97.2 | +16.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 94 | +15.9% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 87.4 | – | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 92.4 | +36.3% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 83.2 | +30.8% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 81.1 | +41.3% | Form 10-Q (filed 2025-05-07) ↗ |
| Q3 2024 | Sep 30, 2024 | 67.8 | +43.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 63.6 | +31.1% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 57.4 | +19.3% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 49.8 | +23.0% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 47.4 | +20.0% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 48.5 | +32.2% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 48.1 | +43.6% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 40.5 | +31.9% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 39.5 | +23.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 36.7 | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 33.5 | – | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 30.7 | – | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2021 | Sep 30, 2021 | 32.1 | – | Form 10-Q (filed 2021-11-04) ↗ |
Breakdown
What makes up BRUKINSA — China Net Product Revenue
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — China Net Product Revenue ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-cn
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.